Country: Canada
Language: English
Source: Health Canada
EPIRUBICIN HYDROCHLORIDE
FRESENIUS KABI CANADA LTD
L01DB03
EPIRUBICIN
2.0MG
SOLUTION
EPIRUBICIN HYDROCHLORIDE 2.0MG
INTRAVENOUS
5ML/25ML/100ML
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0116901002; AHFS:
APPROVED
2008-12-04
_ _ _ _ PRODUCT MONOGRAPH STERILE PR EPIRUBICIN HYDROCHLORIDE INJECTION (Epirubicin Hydrochloride) 2 mg/mL Mfr. Standard ANTINEOPLASTIC AGENT FRESENIUS KABI CANADA LTD. Date of Revision: 45 Vogell Road, Suite 200 January 9, 2017 Richmond Hill, ON L4B 3P6 Submission Control No.: 201601 _Epirubicin Hydrochloride-PM-Eng-v2.0 _ _ _ _ _ _ _ _ _ _ _ _ Page 2 of 38 _ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................. 10 DRUG INTERACTIONS ................................................................................................. 14 DOSAGE AND ADMINISTRATION ............................................................................. 14 OVERDOSAGE ............................................................................................................... 17 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 18 STORAGE AND STABILITY ......................................................................................... 19 SPECIAL HANDLING INSTRUCTIONS ...................................................................... 20 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 21 PART II: SCIENTIFIC INFORMATION ............................................................................... 23 PHARMACEUTICAL INFORMATION ......................................................................... 23 CLINICAL TRIALS ............... Read the complete document